Is GRFS or MDCX more undervalued in 2026?

CirclFi compares Grifols, S.A. (GRFS) and Medicus Pharma Ltd. (MDCX) using 13 institutional-grade valuation models. GRFS has a Quality of Company score of 1.7/10 while MDCX scores 3.2/10.

Which is a better buy — GRFS or MDCX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GRFS and MDCX valuations compare?

GRFS at $7.98 and MDCX at $0.33 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GRFS vs MDCX Valuation Comparison 2026 — Intrinsic Value Analysis

GRFS

Drug Manufacturers - General

Grifols, S.A.

Quality

1.7

out of 10

Value Trap

—

Price

$7.98

Last close

Models

13/13

Active

MDCX

Drug Manufacturers - General

Medicus Pharma Ltd.

Quality

3.2

out of 10

Value Trap

SAFE

Price

$0.33

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	GRFS Fair Value	GRFS Upside	MDCX Fair Value	MDCX Upside
Bayesian DCF	Intrinsic	$2.36	-70.5%	$0.13	-61.7%
Earnings Power Value	Intrinsic	$3.00	-62.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.26	-71.9%	$0.21	-34.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRFS vs MDCX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRFS vs MDCX — Which Stock Is More Undervalued?

MDCX scores higher with a 3.2/10 quality rating vs GRFS's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Grifols, S.A. (GRFS) and Medicus Pharma Ltd. (MDCX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRFS currently trades at $7.98 with a QOC of 1.7/10, while MDCX trades at $0.33 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).